Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis

Company Overview

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Key Stats

• Today's Range: $6.26 to $6.97
• 50-Day Range: $6.46 to $10.40
• 52-Week Range: $5.85 to $160.00
• Volume: 68,576 shs
• Average Volume: 177,511 shs
• Market Capitalization: $3.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Biodexa Pharmaceuticals Stock Analysis - MarketRank™

Biodexa Pharmaceuticals scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Biodexa Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Biodexa Pharmaceuticals are expected to remain at ($1.25) per share in the coming year.

Price to Book Value per Share Ratio

Biodexa Pharmaceuticals has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.49% of the float of Biodexa Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Biodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biodexa Pharmaceuticals has recently decreased by 95.06%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biodexa Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Biodexa Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.49% of the float of Biodexa Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Biodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biodexa Pharmaceuticals has recently decreased by 95.06%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Biodexa Pharmaceuticals this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Biodexa Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biodexa Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.34% of the stock of Biodexa Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 17.51% of the stock of Biodexa Pharmaceuticals is held by institutions.

BDRX Stock Analysis - Frequently Asked Questions

How have BDRX shares performed this year?

Biodexa Pharmaceuticals' stock was trading at $40.50 at the start of the year. Since then, BDRX shares have decreased by 84.2% and is now trading at $6.38.

How were Biodexa Pharmaceuticals' earnings last quarter?

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) announced its quarterly earnings data on Thursday, September, 10th. The company reported ($16,000.00) EPS for the quarter.

When did Biodexa Pharmaceuticals' stock split?

Biodexa Pharmaceuticals's stock reverse split on Thursday, July 31st 2025.The 1-10 reverse split was announced on Tuesday, July 15th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Biodexa Pharmaceuticals?

Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biodexa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biodexa Pharmaceuticals investors own include SoundHound AI (SOUN), Dyne Therapeutics (DYN), NVIDIA (NVDA), Viking Therapeutics (VKTX), TRACON Pharmaceuticals (TCON), ASE Technology (ASX) and BigBear.ai (BBAI).

Company Calendar

• Last Earnings: 9/10/2020
• Today: 8/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BDRX
• Previous Symbol: LON:MTPH
• CIK: 1643918
• Web: www.midatechpharma.com
• Phone: 441235888300
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 1.75
• Quick Ratio: 1.75

Sales & Book Value

• Annual Sales: $470 thousand
• Price / Sales: 8.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.91 per share
• Price / Book: 2.26

Miscellaneous

• Outstanding Shares: 620,000
• Free Float: 618,000
• Market Cap: $4.09 million
• Optionable: Not Optionable
• Beta: 0.98